A novel soluble complement receptor 1 fragment with enhanced therapeutic potential

Area of Science:

• Immunology
• Biochemistry
• Pharmacology

Background:

• Human Complement Receptor 1 (HuCR1) is crucial for regulating complement pathways.
• HuCR1 acts as a receptor for C3b/C4b and accelerates decay of C3/C5 convertase.
• It also serves as a cofactor for factor I-mediated cleavage of C3b and C4b.

Purpose of the Study:

• To identify a minimal soluble fragment of HuCR1 with retained complement regulatory activity.
• To compare the efficacy of various truncated HuCR1 versions in inhibiting complement activation.
• To evaluate the therapeutic potential of the most potent fragment in a kidney damage model.

Main Methods:

• Generation of recombinant, soluble, truncated HuCR1 variants.
• In vitro assays to assess complement activation inhibition.
• In vivo pharmacokinetic studies in mice and a glomerulonephritis model.

Main Results:

• CSL040, a HuCR1 fragment truncated at amino acid 1392, demonstrated superior inhibitory activity.
• CSL040 maintained high affinity for C3b/C4b and exhibited stability.
• Pharmacokinetic studies revealed sialylation impacts CSL040 clearance; it showed improved profile over full HuCR1.
• CSL040 significantly reduced kidney damage, cellular infiltrates, and urine albumin in vivo.

Conclusions:

• CSL040 is a potent, soluble HuCR1 fragment with significant complement inhibitory activity.
• Sialylation influences CSL040 pharmacokinetics, with an improved profile compared to full-length HuCR1.
• CSL040 shows promise as a therapeutic candidate for complement-mediated kidney disorders.